Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Georgia Nephrology LLC

Neither a doctor nor a teaching hospital

Research payments

$1,164,776

457 payments

Through program year 2025, Georgia Nephrology LLC is reported as receiving $1,164,776 in research payments, across 457 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $113,171 11
2024 Research $147,429 25
2023 Research $179,777 46
2022 Research $151,735 17
2021 Research $152,302 79
2020 Research $209,893 119
2019 Research $210,469 160

Breakdown

Who paid Research payments · program years 2019–2025
  1. Retrophin, Inc. $286,460 217 payments
  2. Genentech, Inc. $247,555 23 payments
  3. Akebia Therapeutics Inc $229,190 171 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $134,483 6 payments
  5. Novartis Pharmaceuticals Corporation $96,274 8 payments
  6. Otsuka Pharmaceutical Co., Ltd. $81,875 9 payments
  7. Pfizer Inc. $47,955 8 payments
  8. Aurinia Pharma U.S., Inc. $15,625 4 payments
  9. EMD Serono, Inc. $13,630 9 payments
  10. Lexicon Pharmaceuticals, Inc. $11,729 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomised Double Blind Study to Evaluate Safety and Efficacy of Obinutuzumab in Class III and IV LN $247,555 23 payments
  2. 021Fsgs16010 $177,872 145 payments
  3. 021Igan17001 $97,183 64 payments
  4. Akb-6548-Ci-0014 $78,965 70 payments
  5. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iptacopan (Lnp023) in Complement 3 Glomerulopathy $53,609 4 payments
  6. Robo2 Esoe $41,963 6 payments
  7. Phase II of VIS649 for IgA Nephropathy $41,599 2 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of Vis649 in Participants With Immunoglobulin A (Iga) Nephropathy $40,276 7 payments
  9. An Open-Label, Non-Randomized Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Lnp023 in Subjects With C3 Glomerulopathy $36,166 3 payments
  10. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $34,366 10 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $193,345 151 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record